One of the most common risk factors for stroke is diabetes. Diabetics are 2 to 4 times more likely to have a stroke and are also significantly more likely to show poor functional recovery. In order to determine why diabetes is associated with poor stroke recovery, we tested the hypotheses that diabetes either exacerbates initial stroke damage, or inhibits neuronal circuit plasticity in surviving brain regions that is crucial for successful recovery. Type 1 diabetes was chemically induced in mice four weeks before receiving a targeted photothrombotic stroke in the right forelimb somatosensory cortex to model a chronic diabetic condition. Following stroke, a subset of diabetic mice were treated with insulin to determine if controlling blood glucose levels could improve stroke recovery. Consistent with previous studies, one behavioural test revealed a progressive improvement in sensory function of the forepaw in non-diabetic mice after stroke. By contrast, diabetic mice treated with and without insulin showed persistent deficits in sensori-motor forepaw function. To determine whether these different patterns of stroke recovery correlated with changes in functional brain activation, forepaw evoked responses in the somatosensory cortex were imaged using voltage sensitive dyes at 1 and 14 weeks after stroke. In both diabetic and non-diabetic mice that did not have a stroke, brief mechanical stimulation of the forepaw evoked a robust and near simultaneous depolarization in the primary (FLS1) and secondary somatosensory (FLS2) cortex. One week after stroke, forepaw-evoked responses had not been remapped in the peri-infarct cortex in both diabetic and non-diabetic mice. Fourteen weeks after stroke, forepaw evoked responses in non-diabetic mice re-emerged in the peri-infarct cortex whereas diabetic mice showed very little activation, reminiscent of the 1 week recovery group. Moreover, controlling hyperglycemia using insulin therapy failed to restore sensory evoked responses in the peri-infarct cortex. In addition to these differences in peri-infarct responsiveness, we discovered that stroke was associated with increased responsiveness in FLS2 of non-diabetic, but not diabetic or insulin treated mice. To determine the importance of FLS2 in stroke recovery, we silenced the FLS2 cortex and found that it re-instated behavioural impairments in stroke recovered mice, significantly more so than naïve mice that still had a functioning FLS1. Collectively, these results indicate that both diabetes and the secondary somatosensory cortex play an important role in determining the extent of functional recovery after ischemic cortical stroke. Furthermore, the fact that insulin therapy after stroke did not normalize functional recovery, suggests that prolonged hyperglycemia (before stroke) may induce pathological changes in the brain’s circulation or nervous system that cannot be easily reversed. / Graduate

La douleur neuropathique centrale est une séquelle fréquente après une atteinte du système nerveux centrale. L’impact négatif de ces douleurs sur la qualité de vie des patients ainsi que l’efficacité modérée (40% de répondeurs) des traitements de 1ère intention font de la recherche de thérapies alternatives un enjeu clinique majeur. Depuis plusieurs années, la technique de stimulation magnétique transcrânienne répétée (rTMS) est présentée comme un outil intéressant pour soulager ce type de douleur sans pour autant que son efficacité clinique n’ait été clairement démontrée. Ce travail de thèse s’attache donc à investiguer l’efficacité de la rTMS pour traiter les douleurs neuropathiques centrales. Nous avons dans un premier temps mis en évidence, dans une étude observationnelle, qu’un minimum de 4-5 séances sur deux mois de rTMS à 20HZ sur le cortex moteur primaire (M1) produit un soulagement de la douleur pouvant se maintenir même après une année de stimulation. Afin d’écarter un possible effet placebo, nous avons objectivé l’efficacité antalgique en répliquant ce protocole dans une étude clinique randomisée, contrôlée, en groupes croisés. Les résultats obtenus confirment ceux de l’étude observationnelle puisque que l’effet antalgique de la rTMS active était significativement supérieure à la stimulation placebo pour le critère principal (% de soulagement, +33%) ou l’intensité douloureuse (EVA, -19%), avec 47% de répondeurs. Pour les patients non-répondeurs à la stimulation de M1, nous avons également testé contre placebo, dans une étude randomisée, l’efficacité d’une cible alternative : le cortex somesthésique secondaire (S2). Aucun des patients n’a été soulagé par cette stimulation mais le faible effectif de cette étude ne nous permet pas de conclure définitivement à l’absence d’effet antalgique. Enfin, compte tenu de l’utilisation croissante de nouvelles cibles corticales plus profondes, nous avons à partir de l’enregistrement du champ-magnétique produit par la rTMS dans différents milieux (l’air et modèle ex-vivo), proposé un modèle de distribution de ce champ selon la profondeur de la cible et le type de sonde de stimulation utilisé. Pour conclure, ces travaux objectivent l’effet antalgique de 4 séances de rTMS à 20Hz de M1 sur les douleurs neuropathiques centrales, validant ainsi son utilisation lorsque les traitements de 1ère intention ont échoué. Les résultats obtenus par la stimulation de S2 ainsi que par la modélisation du champ magnétique doivent permettre à de futures études d’explorer de nouvelles cibles corticales pour les patients qui restent encore en échec de traitement. / Central neuropathic pain is a common sequelae after central nervous system injury. Its negative consequences on the quality of life and the moderate efficacy (40% of responders) of first-line treatments make the search for alternative therapies a major clinical challenge. For several years, the technique of repeated transcranial magnetic stimulation (rTMS) is presented as an interesting tool to relieve this sort of pain even though its clinical efficacy has not been clearly demonstrated. The aim of this thesis was to investigate the effectiveness of rTMS to relieve central neuropathic pain.We first demonstrated, in an observational study, that a minimum of 4-5 sessions over two months of rTMS at 20HZ on the primary motor cortex (M1) produces pain relief that can be maintained even after a year of stimulation. In order to rule out a possible placebo effect, we objectified the analgesic efficacy by replicating this protocol in a randomized, controlled, cross-over clinical study. The results obtained confirm those of the observational study since the analgesic effect of the active rTMS was significantly greater than the placebo stimulation for the main criterion (% of pain relief, +33%) or pain intensity (VAS, -19%), with 47% of responders. For patients who did not respond to M1 stimulation, we also tested the efficacy of an alternative target in a randomized study: the secondary somatosensory cortex (S2). None of the patients were relieved by this stimulation, but the small size of this study does not allow us to definitively conclude that there is no analgesic effect. Finally, given the increasing use of new deeper cortical targets in rTMS for pain treatment, we have from the recording of the magnetic field produced by the rTMS in different media (air and ex-vivo model), proposed a magnetic-field distribution model according to the depth of the target and the type of stimulation coils used.To conclude, this work objectify the analgesic effect of 4 rTMS sessions at 20 Hz of M1 to relieve central neuropathic pain, validating its use when first-line treatments have failed. The results obtained by S2 stimulation as well as magnetic field modeling should allow future studies to explore new cortical targets for patients who are still failing treatment